-- Study did not demonstrate statistical significance for primary endpoint of pain reduction from 0 to 96 hours for EXPAREL versus bupivacaine HCl -- -- EXPAREL achieves highly statistically ...
TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...
Pacira Pharmaceuticals, Inc. PCRX announced that it has completed an End-of-Review process with the FDA regarding its supplemental New Drug Application (sNDA) on lead drug Exparel. Exparel is a ...
Good day, and thank you for standing by. Welcome to the Q3 2023 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, ...
FDA expands indications for bupivacaine liposome injectable suspension (Exparel; Pacira BioSciences, Inc.) for use in adult patients as an adductor canal block and a sciatic nerve block in the ...
A nerve block works by preventing pain signals from reaching the brain. There are permanent and temporary options. Both are generally safe procedures. Nerve blocks are an effective way to prevent, ...
Ultrasound-guided nerve blocks for preoperative pain management after hip fracture provide improvements over conventional anesthesia including greater pain reduction and fewer adverse events, results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback